Formiga, FrancescRubio-Rivas, ManuelMora-Lujan, Jose MariaEscudero, Samara CamposFernandez-Madera-Martinez, RosaMendez-Bailon, ManuelDuran-Del-Campo, PedroRiaño-Perez, AndreaGarcia-Sanchez, Francisco-JavierAlcala-Pedrajas, Jose NicolasArnedo-Hernandez, SergioHernandez-Milian, AlmudenaLatorre-Diez, AnaGil-Sanchez, RicardoBoixeda, RamonVicente, JulioCortes, BegoñaPerez, Carmen MellaGuisado-Espartero, Maria EstherCastro, Jose LopezRodriguez-Suarez, SantiagoVarona, Jose FGomez-Huelgas, RicardoRamos-Rincon, Jose Manuel2023-05-032023-05-032021-11-29Formiga F, Rubio-Rivas M, Mora-Luján JM, Escudero SC, Martinez RFM, Mendez-Bailón M, et al. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry. Intern Emerg Med. 2022 Apr;17(3):761-775http://hdl.handle.net/10668/20886Acetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients.enAcetylsalicylic acidCOVID-19CoronavirusMortalityÁrea Sanitaria Norte de CórdobaArea de Gestión Sanitaria Sur de CórdobaAspirinHumansInflammationIntensive Care UnitsRegistriesRetrospective StudiesSARS-CoV-2ThrombosisCOVID-19 Drug Treatmentresearch article34843073Restricted AccessMortalidad HospitalariaInflamaciónTrombosisPuntaje de PropensiónAspirinaNeumonía10.1007/s11739-021-02870-11970-9366PMC8628049https://link.springer.com/content/pdf/10.1007/s11739-021-02870-1.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628049/pdf